Ozempic Vision Loss Lawsuit
(NAION / Sudden Blindness)
New federal litigation alleging GLP-1 receptor agonist drugs like Ozempic, Wegovy, and Mounjaro caused non-arteritic anterior ischemic optic neuropathy (NAION) — sudden, typically irreversible vision loss. Created December 2025 after Harvard study found 4-7x higher risk.
Key Takeaways
- MDL created December 15, 2025 — one of the newest federal MDLs
- Harvard/JAMA study found 4.28x higher risk for diabetics, 7.64x higher for weight loss patients
- June 2025: European Medicines Agency confirmed NAION as "very rare" side effect
- Same judge as MDL-3094 (GI claims) — Judge Karen S. Marston
- Vision loss is typically sudden, painless, and permanent
October 2026 Updates Latest
247 cases now pending (247 total filed), up from 86 in May — growth continues as more NAION patients file claims in the Eastern District of Pennsylvania. Under CMO 12 (July 2, 2026), Judge Karen Marston granted early discovery and motions on general causation and preemption/warning adequacy, the same structure adopted in MDL-3094. Bellwether selection will wait until those issues are decided. Defendants proposed finishing fact discovery in October 2026 and expert discovery by the end of 2026, with briefing in the first quarter of 2027; the court suggested mid-2027 is more realistic.
Failure-to-warn theory, JAMA study, lead counsel & upcoming conferences
U.S. FDA has still NOT added a NAION warning to GLP-1 drug labels — a regulatory gap that remains central to plaintiffs' failure-to-warn theory. Plaintiffs continue to rely on the JAMA Ophthalmology study showing semaglutide patients experienced NAION at over 7x the rate of patients on other medications. CMO 5 (Feb 23, 2026) appointed three co-lead counsel: Parvin Aminolroaya (Seeger Weiss), Jonathan D. Orent (Motley Rice) and Sarah Ruane (Wagstaff & Cartmell). Status conferences are scheduled for Oct 13, Nov 17 and Dec 15, 2026.
Case Growth Tracking
Newly formed MDL tracking case filings since creation in December 2025.
Source: JPML MDL Statistics Reports
Key Facts (October 2026)
| Pending Actions | 247 cases (newly formed MDL) |
| MDL Created | December 15, 2025 |
| Key Defendants | Novo Nordisk Inc./A/S, Eli Lilly and Company |
| Presiding Judge | Hon. Karen S. Marston (E.D. Pennsylvania) |
| Alleged Injury | NAION — sudden, permanent vision loss |
| Key Study | Harvard/Mass Eye & Ear (JAMA Ophthalmol. July 2024) |
| EMA Label Status | June 2025: NAION added as "very rare" side effect |
| FDA Label Status | No NAION warning (as of October 2026) |
| Can You Still File? | Yes, lawsuits are actively being filed |
Harvard JAMA Ophthalmology Study (July 2024)
Researchers at Massachusetts Eye and Ear (Harvard Medical School) observed three NAION cases in one week — all in patients taking semaglutide. The subsequent study of 16,827 patients found significantly elevated risk:
Source: Hathaway JT, et al. JAMA Ophthalmol. 2024;142(8):732-739 (PMID: 38958939)
1 What Is NAION?
Non-arteritic anterior ischemic optic neuropathy (NAION) is the most common cause of sudden optic nerve blindness in adults. It occurs when blood flow to the front of the optic nerve is disrupted, causing permanent damage — sometimes called a "stroke of the optic nerve."
How NAION Presents
- Sudden, painless vision loss — often discovered upon waking
- Usually affects one eye — can affect second eye in 15-25% of cases over 5 years
- Vision loss is typically permanent — no effective treatment exists
- Affects approximately 21,000 Americans annually
2 Why Two GLP-1 MDLs?
The JPML created a separate MDL for NAION claims rather than adding them to MDL-3094 (gastroparesis). Here's how they differ:
| Factor | MDL-3094 (GI) | MDL-3163 (Vision) |
|---|---|---|
| Primary Injuries | Gastroparesis, ileus, intestinal obstruction | NAION, sudden vision loss, blindness |
| Case Count | ~4,000+ cases | ~247 cases |
| Established | February 2024 | December 2025 |
| Expert Type | Gastroenterology | Ophthalmology, Neuro-ophthalmology |
| FDA Warning | Oct 2025: Gastroparesis warning added | No U.S. warning |
3 Regulatory Status: EMA vs FDA
European Medicines Agency (June 2025)
The EMA's Pharmacovigilance Committee (PRAC) concluded that NAION is a "very rare" side effect of semaglutide. They recommended adding NAION to European drug labels and advising patients to stop the medication if NAION is confirmed.
U.S. FDA (As of October 2026)
NAION is NOT included in U.S. drug labels: no current label for Ozempic, Wegovy, oral semaglutide (Rybelsus/Ozempic tablets), Saxenda, Trulicity, Mounjaro, or Zepbound mentions NAION or optic neuropathy. FDA's adverse-event monitoring page lists NAION for GLP-1 drugs with the note "FDA is evaluating the need for regulatory action." This regulatory gap is central to plaintiffs' failure-to-warn claims.
4 Scientific Evidence
Key Studies
Proposed Mechanisms (Under Investigation)
- • Rapid metabolic changes affecting optic nerve perfusion
- • Enhanced sympathetic activity impacting vascular tone
- • Pre-existing microvascular damage in diabetic patients
Dr. Joseph Rizzo at Harvard has received NIH funding to study GLP-1 receptors in optic nerve tissue.
5 Do You Qualify?
Eligibility for NAION Claims
- Took a GLP-1 drug — Ozempic, Wegovy, Rybelsus, Mounjaro, Zepbound, or similar
- Diagnosed with NAION — Confirmed by ophthalmologist or neuro-ophthalmologist
- Sudden vision loss — Typically painless, often discovered upon waking
- Medical documentation — Prescription records, eye exam records, diagnosis confirmation
6 Frequently Asked Questions
Is NAION vision loss permanent?
Why hasn't the FDA added a warning?
What if I have both GI and vision problems?
Are Mounjaro and Zepbound included?
When will there be trials?
7 Key Timeline
Research showing 4-7x higher NAION risk sparks litigation
European regulators begin investigating NAION-semaglutide link
NAION added to European drug labels as "very rare" side effect
State-level consolidation of NAION and GI claims
Federal NAION cases consolidated before Judge Marston in E.D. Pennsylvania
Sources & References
8 official sources cited• JPML Transfer Order MDL-3163 (December 15, 2025)
• Hathaway JT, et al. "Risk of Nonarteritic Anterior Ischemic Optic Neuropathy in Patients Prescribed Semaglutide." JAMA Ophthalmol. 2024;142(8):732-739 (PMID: 38958939)
• Cai CX, et al. "Semaglutide and Nonarteritic Anterior Ischemic Optic Neuropathy." JAMA Ophthalmol. 2025;143(4):304-314 (PMID: 39976940)
• European Medicines Agency — Wegovy Product Information (June 2025 PRAC decision)
• American Academy of Ophthalmology — "What Is Ischemic Optic Neuropathy?"
• FDA DailyMed — Ozempic Prescribing Information (October 2025)
• JPML MDL Statistics Report (October 2026)
• U.S. District Court, Eastern District of Pennsylvania — MDL-3163 docket
Attorney Advertising. The information on this page is provided for general informational purposes only and does not constitute legal advice. No attorney-client relationship is created by accessing or using this content.
Every case is unique, and results depend on the specific facts and circumstances involved. Past settlement amounts and case outcomes do not guarantee similar results in your case. If you believe you have a legal claim, you should consult with a licensed attorney in your jurisdiction who can evaluate your specific situation.